PUBLISHER: Allied Market Research | PRODUCT CODE: 1344418
PUBLISHER: Allied Market Research | PRODUCT CODE: 1344418
According to a new report published by Allied Market Research, titled, "Helicobacter Pylori Diagnostics Market," The helicobacter pylori diagnostics market was valued at $552.65 million in 2022, and is estimated to reach $926.8 million by 2032, growing at a CAGR of 5.3% from 2023 to 2032.
The helicobacter pylori diagnostics market was negatively impacted during the lockdown period owing to decrease in demand for H. pylori testing devices. In addition, decrease in patient visits to healthcare facilities due to fear of infection led to reduce the number of patients undergoing H. pylori testing, which negatively impacted the market growth.
H. pylori infection is a major risk factor for gastric cancer. Increase in the incidence of gastric cancer there is a growing demand for early detection and treatment of H. pylori infections that propels helicobacter pylori diagnostics market growth. For instance, American Cancer Society's estimated for stomach cancer (also known as gastric cancer) in the U.S. 2023. Thus, the rise in cases of gastric cancer drives the demand for H. pylori diagnostic testing and further propels market growth.
In addition, growing demand for non-invasive tests boosts market growth. Patients prefer non-invasive diagnostic tests such as breath tests and stool antigen tests over invasive tests such as endoscopy. Thus, demand for non-invasive tests has driven the development of new diagnostic technologies which further fuel the growth during helicobacter pylori diagnostics market forecast.
The growth of the helicobacter pylori diagnostics market is expected to be driven by high potential in untapped, emerging markets, due to availability of improved healthcare infrastructure, increase in unmet healthcare needs, and rise in prevalence of infectious diseases.
Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, significant investments by government to improve healthcare infrastructure, and development of the medical tourism industry in emerging countries.
Moreover, early diagnosis and treatment of H. pylori infections can help to prevent the development of more serious complications, such as gastric cancer that supports market growth. As a result, there is an increase in demand for H. pylori testing to facilitate early detection and treatment. H. pylori infections are associated with several gastrointestinal diseases, including peptic ulcer disease and gastric cancer. Thus, a rise in awareness of these diseases led to an increase in the demand for H. pylori testing and further boost the grwoth of the helicobacter pylori diagnostics market size.
The demand for helicobacter pylori diagnostics is not only limited to developed countries but is also being witnessed in the developing countries, such as China, Brazil, and India, which fuel the growth of the market. Factors such as rise in adoption of point of care testing, and increase in awareness toward early diagnosis, further drive the growth of the market.
Lack of awareness about the H. pylori infection among the general population is a restraining factor for the growth of the H. pylori diagnostics market. Many people are not aware of the symptoms and complications associated with H. pylori infection, which leads to delayed diagnosis and treatment. Regulatory issues related to the approval of new diagnostic tests for H. pylori may also act as a restraining factor for market growth. The regulatory approval process is time-consuming and expensive, which may limit the availability of new and innovative H. pylori diagnostics tests in the market.
The outbreak of COVID-19 has disrupted workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The global helicobacter pylori diagnostics industry experienced a decline in 2021 due to global economic recession led by COVID-19. The COVID-19 pandemic has led to the postponement or cancellation of non-urgent diagnostic procedures, including H. pylori testing. This has resulted in a decline in the demand for H. pylori testing, which has affected the revenue of companies operating in this market. In addition, pandemic also led to a decrease in patient visits to healthcare facilities due to fear of infection and the implementation of social distancing measures. This reduced the number of patients undergoing H. pylori testing, which impacted the market negatively.
However, the market is recovering after 2022, and show stable growth for the Helicobacter pylori diagnostics market in the coming future. This is attributed to the development of innovative and cost-effective diagnostic technologies and the availability of effective treatment options for H. pylori infection are expected to drive the growth of the H. pylori diagnostics market in the coming years.
The helicobacter pylori diagnostics market is segmented into test type, method, end user, and region. By test type, the market is categorized into non-invasive test and invasive test. The non-invasive test segment is further divided into the serology test, stool antigen test, and carbon urea breath test. On the basis of method, the market is segregated into laboratory-based test and point of care test. By end user, the market is classified into hospitals, diagnostic laboratories, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.